Join to View Full Profile
Duke Univ Sch of MedDurham, NC 27710
Dr. Dunnmon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Cardiovascular Disease, 1987 - 1990- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1984 - 1987
Duke University School of MedicineClass of 1984
Certifications & Licensure
VA State Medical License 1996 - 2026
NC State Medical License 1985 - 2025
DC State Medical License 1997 - 1998
MD State Medical License 1997 - 1998
TX State Medical License 1986 - 1996
WA State Medical License 1990 - 1991
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation Start of enrollment: 2000 Sep 01
Publications & Presentations
PubMed
- Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum.Sharmila Dorbala, Rosalyn Adigun, Kevin M Alexander, Michela Brambatti, Sarah A M Cuddy
JACC. Cardiovascular Imaging. 2025-02-20 - 4 citationsAn electrocardiogram-based AI algorithm for early detection of pulmonary hypertension.Hilary M DuBrock, Tyler E Wagner, Katherine Carlson, Corinne L Carpenter, Samir Awasthi
The European Respiratory Journal. 2024-07-01 - 2 citationsPathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis.James Signorovitch, Jialu Zhang, David Brown, Preston Dunnmon, Liang Xiu
Therapeutic Innovation & Regulatory Science. 2024-07-01
Press Mentions
FDA Advisory Panel Recommends Approval of Bayer Lung DrugAugust 6th, 2013- FDA Panel Revisits Avandia; Likely Too Late for Diabetes DrugJune 5th, 2013
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
